Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

American Journal of Hematology

Volumn 89, Issue 7, 2014, Pages 732-742

  Gambacorti Passerini, Carlo ^a   Brümmendorf, Tim H ^b,c   Kim, Dong Wook ^d   Turkina, Anna G ^e   Masszi, Tamas ^f   Assouline, Sarit ^g   Durrant, Simon ^h   Kantarjian, Hagop M ⁱ   Khoury, H Jean ^j   Zaritskey, Andrey ^k   Shen, Zhi Xiang ^l   Jin, Jie ^m   Vellenga, Edo ⁿ   Pasquini, Ricardo ^o   Mathews, Vikram ^p   Cervantes, Francisco ^q   Besson, Nadine ^r   Turnbull, Kathleen ^r   Leip, Eric ^r   Kelly, Virginia ^r   Cortes, Jorge E ⁱ   more..

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d The Catholic University of Korea   (South Korea)

^e NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^f Szent Laszlo Hospital   (Hungary)

^g MCGILL UNIVERSITY   (Canada)

^h ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j EMORY UNIVERSITY   (United States)

^k ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE   (Russian Federation)

^l SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^m ZHEJIANG UNIVERSITY   (China)

ⁿ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^o FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^p CHRISTIAN MEDICAL COLLEGE   (India)

^q UNIVERSITY OF BARCELONA   (Spain)

^r PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIEMETIC AGENT; ATROPINE PLUS DIPHENOXYLATE; BCR ABL PROTEIN; BICARBONATE; BOSUTINIB; CREATININE; IMATINIB; LOPERAMIDE; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ARTICLE; ASTHENIA; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILL; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; CREATININE BLOOD LEVEL; CYTOGENETICS; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INFLUENZA; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OROPHARYNX PAIN; OVERALL SURVIVAL; PANCREATITIS; PERIPHERAL EDEMA; PLEURA EFFUSION; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; BENZAMIDES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; NITRILES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902843429     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23728     Document Type: Article

References (27)

1. Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999;341(3):164-172.
2. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27(35):6041-6051.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Chronic Myelogenous Leukemia. Version 3.2013. Available at: http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf. Accessed December 5, 2013.
4. Diamond JM, Melo JV. Mechanisms of resistance to BCR-ABL kinase inhibitors. Leuk Lymphoma 2011;52(Suppl. 1):12-22.
5. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22(6):1200-1206.
6. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354(24):2542-2551.
7. Kantarjian H, Pasquini R, Levy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115(18):4136-4147.
8. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117(4):1141-1145.
9. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12(9):841-851.
10. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119(5):1123-1129.
11. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26(19):3204-3212.
12. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95(2):232-240.
13. Giles FJ, Abruzzese E, Rosti G, et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 2010;24(7):1299-1301.
14. Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007;109(2):497-499.
15. Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008;111(4):2329-2338.
16. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006;66(23):11314-11322.
17. Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23(3):477-485.
18. Gambacorti-Passerini C, Tornaghi L, Cavagnini F, et al. Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet 2003;361(9373):1954-1956.
19. Jabbour E, Cortes JE, Ghanem H, et al. Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther 2008;8(1):99-110.
20. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25(25):3908-3914.
21. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009;27(3):469-471.
22. Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118(17):4567-4576.
23. Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119(15):3403-3412.
24. Gambacorti-Passerini C, Cortes JE, Khoury HJ, et al. Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200. J Clin Oncol 2010;28(Suppl.):Abstract 6509.
25. Jones D, Kamel-Reid S, Bahler D, et al. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J Mol Diagn 2009;11(1):4-11.
26. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012;30(28):3486-3492.
27. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108(6):1809-1820.